Abstract
Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
Radiation oncology (London, England), v 9(1), pp 41-41
30 Jan 2014
PMID: 24479954
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: This retrospective study aims to assess the usefulness of SUVmax from FDG-PET imaging as a prognosticator for primary biopsy-proven stage I NSCLC treated with SBRT.
Methods: This study includes 95 patients of median age 77 years, with primary, biopsy-confirmed peripheral stage IA/IB NSCLC. All patients were treated with 60Gy in 3 fractions with a median treatment time of six days. Local, regional, and distant failures were evaluated independently according to the terms of RTOG1021. Local, regional, and distant control, overall-and progression-free survival were estimated by the Kaplan-Meier method. Cox proportional hazards regression was performed to determine whether SUVmax, age, KPS, gender, tumor size/T stage, or smoking history influenced outcomes. SUVmax was evaluated as both a continuous and as a dichotomous variable using a cutoff of <5 and >= 5.
Results: Median follow-up for the cohort was 16 months. Median OS and PFS were 25.3 and 40.3 months, respectively. SUV with a cutoff value of 5 predicted for OS and PFS (p = .024 for each) but did not achieve significance for LC (p = .256). On Cox univariate regression analysis, SUV as a dichotomous variable predicted for both OS and PFS (p = .027 and p = .030, respectively). Defined as a continuous variable, SUVmax continued to predict for OS and PFS (p = .032 and p = .003), but also predicted LC (p = .045) and trended toward significance for DC (p = .059). SUVmax did not predict for OS as a dichotomous or continuous variable. It did, however, predict for PFS as a continuous variable (p = .008), neared significance for local control (p = .057) and trended towards, significance for distant control (p = .092).
Conclusions: SUVmax appears to be a statistically and clinically significant independent prognostic marker for progression-free survival in patients with stage I NSCLC treated with SBRT. Prospective studies to more accurately define the role of tumor FDG uptake in the prognosis of NSCLC are warranted.
Metrics
Details
- Title
- Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
- Creators
- Zachary D. Horne - UPMC Hillman Cancer CenterDavid A. Clump - UPMC Hillman Cancer CenterJohn A. Vargo - UPMC Hillman Cancer CenterSamir Shah - UPMC Hillman Cancer CenterSushil Beriwal - UPMC Hillman Cancer CenterSteven A. Burton - UPMC Hillman Cancer CenterAnnette E. Quinn - UPMC Hillman Cancer CenterMatthew J. Schuchert - University of Pittsburgh Medical CenterRodney J. Landreneau - University of Pittsburgh Medical CenterNeil A. Christie - University of Pittsburgh Medical CenterJames D. Luketich - University of Pittsburgh Medical CenterDwight E. Heron - UPMC Hillman Cancer Center
- Publication Details
- Radiation oncology (London, England), v 9(1), pp 41-41
- Publisher
- Springer Nature
- Number of pages
- 6
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000331630900002
- Scopus ID
- 2-s2.0-84893162288
- Other Identifier
- 991021897391004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging